Tolerability and efficacy of IMpower133 regimen modified for dialysis patients with extensive‐stage small cell lung cancer: Two case reports

The IMpower133 regimen, composed of atezolizumab/etoposide (VP‐16)/carboplatin (CBDCA), is the standard first‐line treatment for extensive‐stage small cell lung cancer (ES‐SCLC). However, the safety and efficacy of triplet therapy in patients receiving dialysis have not been sufficiently evaluated....

Descripción completa

Detalles Bibliográficos
Autores principales: Watari, Naokazu, Yamaguchi, Kakuhiro, Masuda, Takeshi, Ito, Noriaki, Sakamoto, Shinjiro, Horimasu, Yasushi, Miyamoto, Shintaro, Nakashima, Taku, Iwamoto, Hiroshi, Fujitaka, Kazunori, Hamada, Hironobu, Hattori, Noboru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563152/
https://www.ncbi.nlm.nih.gov/pubmed/34587368
http://dx.doi.org/10.1111/1759-7714.14166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563152/
https://www.ncbi.nlm.nih.gov/pubmed/34587368
http://dx.doi.org/10.1111/1759-7714.14166

Ejemplares similares